Annovis Bio (ANVS)
NYSE:ANVS
Total Valuation
Annovis Bio has a market cap or net worth of $60.11M. The enterprise value is -$19.49B.
Market Cap$60.11M
Enterprise Value-$19.49B
Share Statistics
Annovis Bio has 28,355,263 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,355,263
Owned by Insiders15.22%
Owned by Institutions1.63%
Financial Efficiency
Annovis Bio’s return on equity (ROE) is -1.71 and return on invested capital (ROIC) is -170.21%.
Return on Equity (ROE)-1.71
Return on Assets (ROA)-1.37
Return on Invested Capital (ROIC)-170.21%
Return on Capital Employed (ROCE)-1.70
Revenue Per Employee0.00
Profits Per Employee-3.61B
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Annovis Bio is ―. Annovis Bio’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio4.22
Price to Fair Value4.22
Price to FCF>-0.01
Price to Operating Cash Flow-0.07
PEG Ratio0.02
Income Statement
In the last 12 months, Annovis Bio had revenue of 0.00 and earned -28.85M in profits. Earnings per share was -1.40.
Revenue0.00
Gross Profit0.00
Operating Income-29.70M
Pretax Income-28.85M
Net Income-28.85M
EBITDA-29.70M
Earnings Per Share (EPS)-1.40
Cash Flow
In the last 12 months, operating cash flow was -852.66M and capital expenditures -5.00, giving a free cash flow of -852.66M billion.
Operating Cash Flow-852.66M
Free Cash Flow-852.66M
Free Cash Flow per Share-30.07
Dividends & Yields
Annovis Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.22
52-Week Price Change61.70%
50-Day Moving Average2.56
200-Day Moving Average2.73
Relative Strength Index (RSI)39.58
Average Volume (3m)406.81K
Important Dates
Annovis Bio upcoming earnings date is May 19, 2026, Before Open (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Annovis Bio as a current ratio of 5.80, with Debt / Equity ratio of 0.00%
Current Ratio5.80
Quick Ratio5.80
Debt to Market Cap0.00
Net Debt to EBITDA657.76
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Annovis Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Annovis Bio EV to EBITDA ratio is 655.36, with an EV/FCF ratio of 0.76.
EV to Sales0.00
EV to EBITDA655.36
EV to Free Cash Flow0.76
EV to Operating Cash Flow0.76
Balance Sheet
Annovis Bio has $19.53B in cash and marketable securities with $0.00 in debt, giving a net cash position of $19.53B billion.
Cash & Marketable Securities$19.53B
Total Debt$0.00
Net Cash$19.53B
Net Cash Per Share$688.84
Tangible Book Value Per Share$0.82
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Annovis Bio is $12.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.50
Price Target Upside489.62% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast62.84%